Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:New treatment approaches for Clostridioides difficile infections : alternatives to antibiotics and fecal microbiota transplantation
Authors:ID Bratkovič, Tomaž (Author)
ID Zahirović, Abida, Institut "Jožef Stefan" (Author)
ID Bizjak, Maruša, Institut "Jožef Stefan" (Author)
ID Rupnik, Maja (Author)
ID Štrukelj, Borut, Institut "Jožef Stefan" (Author)
ID Berlec, Aleš, Institut "Jožef Stefan" (Author)
Files:URL URL - Source URL, visit https://www.tandfonline.com/doi/full/10.1080/19490976.2024.2337312
 
.pdf PDF - Presentation file, download (4,12 MB)
MD5: 2BA84E99F7595644E3E5F39545EA78AD
 
Language:English
Typology:1.02 - Review Article
Organization:Logo IJS - Jožef Stefan Institute
Abstract:Clostridioides difficile causes a range of debilitating intestinal symptoms that may be fatal. It is particularly problematic as a hospital-acquired infection, causing significant costs to the health care system. Antibiotics, such as vancomycin and fidaxomicin, are still the drugs of choice for C. difficile infections, but their effectiveness is limited, and microbial interventions are emerging as a new treatment option. This paper focuses on alternative treatment approaches, which are currently in various stages of development and can be divided into four therapeutic strategies. Direct killing of C. difficile (i) includes beside established antibiotics, less studied bacteriophages, and their derivatives, such as endolysins and tailocins. Restoration of microbiota composition and function (ii) is achieved with fecal microbiota transplantation, which has recently been approved, with standardized defined microbial mixtures, and with probiotics, which have been administered with moderate success. Prevention of deleterious effects of antibiotics on microbiota is achieved with agents for the neutralization of antibiotics that act in the gut and are nearing regulatory approval. Neutralization of C. difficile toxins (iii) which are crucial virulence factors is achieved with antibodies/antibody fragments or alternative binding proteins. Of these, the monoclonal antibody bezlotoxumab is already in clinical use. Immunomodulation (iv) can help eliminate or prevent C. difficile infection by interfering with cytokine signaling. Small-molecule agents without bacteriolytic activity are usually selected by drug repurposing and can act via a variety of mechanisms. The multiple treatment options described in this article provide optimism for the future treatment of C. difficile infection.
Keywords:microbiota, immunomodulators
Publication status:Published
Publication version:Version of Record
Submitted for review:29.01.2024
Article acceptance date:27.03.2024
Publication date:09.04.2024
Publisher:Taylor & Francis
Year of publishing:2024
Number of pages:str. 1-34
Numbering:Vol. 16, iss. 1
Source:Velika Britanija
PID:20.500.12556/DiRROS-21242 New window
UDC:615
ISSN on article:1949-0984
DOI:10.1080/19490976.2024.2337312 New window
COBISS.SI-ID:192145923 New window
Copyright:© 2024 The Author(s).
Note:Nasl. z nasl. zasl.; Soavtorji: Abida Zahirović, Maruša Bizjak, Maja Rupnik, Borut Štrukelj, Aleš Berlec; Opis vira z dne 11. 4. 2024;
Publication date in DiRROS:17.01.2025
Views:264
Downloads:126
Metadata:XML DC-XML DC-RDF
:
BRATKOVIČ, Tomaž, ZAHIROVIĆ, Abida, BIZJAK, Maruša, RUPNIK, Maja, ŠTRUKELJ, Borut and BERLEC, Aleš, 2024, New treatment approaches for Clostridioides difficile infections : alternatives to antibiotics and fecal microbiota transplantation. Gut microbes [online]. 2024. Vol. 16, no. 1, p. 1–34. [Accessed 17 April 2025]. DOI 10.1080/19490976.2024.2337312. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=21242
Copy citation
  
Share:Bookmark and Share


Searching for similar works...Please wait....
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Gut microbes
Publisher:Landes Bioscience
ISSN:1949-0984
COBISS.SI-ID:522490137 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J7-4420
Name:Selektivno mehansko odstranjevanje bakterijskih biofilmov s konjugiranimi magnetnimi nanodelci

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J4-3096
Name:Rekombinantni probiotiki kot bio-alternativni protimikrobni pristop proti bakteriji Clostridioides difficile

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0127
Name:Farmacevtska biotehnologija: znanost za zdravje

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0387
Name:Črevesna mikrobiota - vloga v zdravju in pri boleznih

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:Z4-4566
Name:Razvoj mlečnokislinskih bakterij za ciljano dostavo protitumorskih učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0420
Name:Napredna imunološka zdravila in celični pristopi v farmaciji

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:09.04.2024
Applies to:VoR

Secondary language

Language:Slovenian
Title:New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation
Keywords:mikrobiota, imunomodulacija


Back